---
title: Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory
  Acute Leukemia (AUGMENT-101)
date: '2024-08-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39121437/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240810182936&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSION: Revumenib led to high remission rates with a predictable
  safety profile in R/R KMT2Ar acute leukemia. To our knowledge, this trial represents
  the largest evaluation of a targeted therapy for these ...'
disable_comments: true
---
CONCLUSION: Revumenib led to high remission rates with a predictable safety profile in R/R KMT2Ar acute leukemia. To our knowledge, this trial represents the largest evaluation of a targeted therapy for these ...